Cargando…

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma

Detalles Bibliográficos
Autores principales:	Franchini, Massimo, Glingani, Claudia, Bellani, Angela, Cicorella, Nicola, Amadini, Alessandro, De Donno, Giuseppe, Casari, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055517/ https://www.ncbi.nlm.nih.gov/pubmed/33931305 http://dx.doi.org/10.1016/j.tracli.2021.04.003

Ejemplares similares

Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial
por: Franchini, Massimo, et al.
Publicado: (2021)

The Three Pillars of COVID-19 Convalescent Plasma Therapy
por: Franchini, Massimo, et al.
Publicado: (2021)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review
por: Grisolia, Gianpaolo, et al.
Publicado: (2020)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review
por: Franchini, Massimo, et al.
Publicado: (2021)

Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations
por: Franchini, M., et al.
Publicado: (2022)

Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
por: Perotti, Cesare, et al.
Publicado: (2020)

Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience
por: Franchini, Massimo, et al.
Publicado: (2022)

Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients
por: Franchini, Massimo, et al.
Publicado: (2022)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent Plasma for the Treatment of Severe COVID-19
por: Franchini, Massimo, et al.
Publicado: (2021)

Why should we use convalescent plasma for COVID-19?
por: Franchini, Massimo
Publicado: (2020)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report
por: De Rienzo, Mafalda, et al.
Publicado: (2021)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure
por: Keitel, Verena, et al.
Publicado: (2021)

Convalescent plasma therapy for persistent hepatitis E virus infection
por: Ankcorn, Michael, et al.
Publicado: (2019)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for administration of passive antibodies against viral agents
por: Di Minno, Giovanni, et al.
Publicado: (2020)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review
por: Zaffanello, Marco, et al.
Publicado: (2021)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient
por: Biava, Mirella, et al.
Publicado: (2017)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery
por: Basheer, Maamoun, et al.
Publicado: (2021)

Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
por: Marconato, Maddalena, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

COVID-19: Pharmacology and kinetics of viral clearance
por: Farina, Nicola, et al.
Publicado: (2020)

Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection
por: Thimme, Robert, et al.
Publicado: (2001)

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients
por: Ling, Yun, et al.
Publicado: (2020)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
por: Thomopoulos, Thomas P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtj03e51ubuddr5nrqb796okul